RIIAD1

Across TCGA pan-cancer cohorts, RIIAD1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RIIAD1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher RIIAD1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RIIAD1 expression acts as an unfavorable survival marker.

THYM and SCLC are the cancer types where RIIAD1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
SCLC	OS	Median	All	0.055	0.708	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RIIAD1–THYM (OS)

Open the THYM breakdown →